Drug Trial Radar · NCT00364546
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
Last checked: Nov 19, 2026Latest source record: Jun 9, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
877
Actual
Start
Jul 2006
Primary completion
Jun 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Grünenthal GmbH
- First posted
- Aug 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of CG5503 base Immediate Release(IR) 50 mg or 100 mg taken every 4 to 6 hours as needed over the long-term exposure of 90 days in patients who have chronic pain.
Conditions
- Osteoarthritis
- Pain Intensity Assessment
- Arthralgia
- Sciatica
- Low Back Pain
Interventions
CG 5503;tapentadolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcomes include incidence of adverse events, changes in laboratory measures, results of physical exams, and results of 12-Lead ECG.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.